Combination of Pharmacophore Matching, 2D Similarity Search, and In Vitro Biological Assays in the Selection of Potential 5‐HT6 Antagonists from Large Commercial Repositories

Rapid in silico selection of target‐focused libraries from commercial repositories is an attractive and cost‐effective approach. If structures of active compounds are available, rapid 2D similarity search can be performed on multimillion compound databases, but the generated library requires further focusing. We report here a combination of the 2D approach with pharmacophore matching which was used for selecting 5‐HT6 antagonists. In the first screening round, 12 compounds showed >85% antagonist efficacy of the 91 screened. For the second‐round (hit validation) screening phase, pharmacophore models were built, applied, and compared with the routine 2D similarity search. Three pharmacophore models were created based on the structure of the reference compounds and the first‐round hit compounds. The pharmacophore search resulted in a high hit rate (40%) and led to novel chemotypes, while 2D similarity search had slightly better hit rate (51%), but lacking the novelty. To demonstrate the power of the virtual screening cascade, ligand efficiency indices were also calculated and their steady improvement was confirmed.

[1]  H. Greiner,et al.  2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists. , 2005, Bioorganic & medicinal chemistry letters.

[2]  S. L. Dixon,et al.  The hidden component of size in two-dimensional fragment descriptors: side effects on sampling in bioactive libraries. , 1999, Journal of medicinal chemistry.

[3]  David E. Shaw,et al.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results , 2006, J. Comput. Aided Mol. Des..

[4]  C. Marsden,et al.  5-ht6 receptors. , 2004, Current drug targets. CNS and neurological disorders.

[5]  G. Martin,et al.  Classification and nomenclature of 5-HT receptors: a comment on current issues , 1995, Behavioural Brain Research.

[6]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[7]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[8]  D. Sibley,et al.  Cloning, Characterization, and Chromosomal Localization of a Human 5‐HT6 Serotonin Receptor , 1996, Journal of neurochemistry.

[9]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[10]  G. Keserű,et al.  Integration of virtual and high throughput screening in lead discovery settings. , 2011, Combinatorial chemistry & high throughput screening.

[11]  Sean L Kitson,et al.  5-hydroxytryptamine (5-HT) receptor ligands. , 2007, Current pharmaceutical design.

[12]  V. Madison,et al.  Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model. , 2008, Journal of medicinal chemistry.

[13]  C. Abad-Zapatero,et al.  Ligand efficiency indices for effective drug discovery , 2007, Expert opinion on drug discovery.

[14]  Robert C. Glen,et al.  Similarity Metrics and Descriptor Spaces — Which Combinations to Choose , 2007 .

[15]  Y Z Chen,et al.  Virtual screening methods as tools for drug lead discovery from large chemical libraries. , 2012, Current medicinal chemistry.

[16]  Peter Willett,et al.  Similarity-based virtual screening using 2D fingerprints. , 2006, Drug discovery today.

[17]  Li Di,et al.  Drug-like property concepts in pharmaceutical design. , 2009, Current pharmaceutical design.

[18]  Leonardo Pardo,et al.  A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists. , 2005, Journal of medicinal chemistry.

[19]  A. Brown,et al.  5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist. , 1999, Journal of medicinal chemistry.

[20]  P P Humphrey,et al.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.

[21]  J. Bockaert,et al.  5-HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture. , 1994, Neuroreport.

[22]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[23]  G. Savettieri,et al.  Association of the 5-HT6 receptor gene polymorphism C267T with Parkinson’s disease , 2002, Neurology.

[24]  6-Bicyclopiperazinyl-1-arylsulfonylindoles and 6-bicyclopiperidinyl-1-arylsulfonylindoles derivatives as novel, potent, and selective 5-HT6 receptor antagonists. , 2000, Bioorganic & medicinal chemistry letters.

[25]  M. R. Akl,et al.  Optimization, pharmacophore modeling and 3D-QSAR studies of sipholanes as breast cancer migration and proliferation inhibitors. , 2014, European journal of medicinal chemistry.

[26]  S. Rees,et al.  A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor. , 1997, Analytical biochemistry.

[27]  Anna Gulyás-Forró,et al.  Design, Selection, and Evaluation of a General Kinase‐Focused Library , 2009, ChemMedChem.

[28]  A. Robichaud,et al.  5‐HT6 antagonists as potential treatment for cognitive dysfunction , 2009 .

[29]  P. Willett,et al.  A Comparison of Some Measures for the Determination of Inter‐Molecular Structural Similarity Measures of Inter‐Molecular Structural Similarity , 1986 .

[30]  Tudor I. Oprea,et al.  Strategies for compound selection. , 2004, Current drug discovery technologies.

[31]  X. Codony,et al.  Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. , 2008, Pharmacology & therapeutics.

[32]  Andrzej J Bojarski,et al.  Pharmacophore models for metabotropic 5-HT receptor ligands. , 2006, Current topics in medicinal chemistry.

[33]  R Marsault,et al.  Transfected Aequorin in the Measurement of Cytosolic Ca2+ Concentration ([Ca2+]c) , 1995, The Journal of Biological Chemistry.

[34]  M. Garcia-Alloza,et al.  Differential Involvement of 5-HT1B/1D and 5-HT6 Receptors in Cognitive and Non-cognitive Symptoms in Alzheimer's Disease , 2004, Neuropsychopharmacology.

[35]  Leonardo Pardo,et al.  Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease. , 2014, Journal of medicinal chemistry.

[36]  Marvin Johnson,et al.  Concepts and applications of molecular similarity , 1990 .

[37]  J. Holenz,et al.  Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents. , 2006, Drug discovery today.

[38]  Varun Khanna,et al.  Physiochemical property space distribution among human metabolites, drugs and toxins , 2009, BMC Bioinformatics.

[39]  D. Bennett,et al.  Alzheimer disease in the US population: prevalence estimates using the 2000 census. , 2003, Archives of neurology.

[40]  Robert C. Glen,et al.  Similarity Metrics and Descriptor Spaces – Which Combinations to Choose? , 2006 .

[41]  Hongma Sun,et al.  Pharmacophore-based virtual screening. , 2008, Current medicinal chemistry.

[42]  Björn Krüger,et al.  The holistic integration of virtual screening in drug discovery. , 2013, Drug discovery today.

[43]  A. Hopkins,et al.  The role of ligand efficiency metrics in drug discovery , 2014, Nature Reviews Drug Discovery.

[44]  W. L. Jorgensen The Many Roles of Computation in Drug Discovery , 2004, Science.

[45]  G. Bernardi,et al.  Endogenous Serotonin Excites Striatal Cholinergic Interneurons via the Activation of 5-HT 2C, 5-HT6, and 5-HT7 Serotonin Receptors: Implications for Extrapyramidal Side Effects of Serotonin Reuptake Inhibitors , 2007, Neuropsychopharmacology.

[46]  P. Bonaventure,et al.  Recent Advances on the 5-HT5A, 5-HT6 and 5-HT7 Receptors , 2008 .

[47]  I. Hajdú,et al.  Rapid in silico selection of an MCHR1 antagonists’ focused library from multi-million compounds’ repositories: biological evaluation , 2014, Medicinal Chemistry Research.

[48]  Claire Mount,et al.  Alzheimer disease: progress or profit? , 2006, Nature Medicine.

[49]  S. Tkachenko,et al.  Synthesis and structure-activity relationship (SAR) of (5,7-disubstituted 3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methylamines as potent serotonin 5-HT(6) receptor (5-HT(6)R) antagonists. , 2011, Journal of medicinal chemistry.

[50]  Beáta Flachner,et al.  Combination of 2D/3D Ligand-Based Similarity Search in Rapid Virtual Screening from Multimillion Compound Repositories. Selection and Biological Evaluation of Potential PDE4 and PDE5 Inhibitors , 2014, Molecules.

[51]  Richard Morphy,et al.  The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. , 2006, Journal of medicinal chemistry.

[52]  Jürgen Bajorath,et al.  Comparison of 2D Fingerprint Methods for Multiple‐Template Similarity Searching on Compound Activity Classes of Increasing Structural Diversity , 2007, ChemMedChem.

[53]  György Dormán,et al.  Combining 2D and 3D in silico methods for rapid selection of potential PDE5 inhibitors from multimillion compounds’ repositories: biological evaluation , 2011, Molecular Diversity.

[54]  Sheng-Yong Yang,et al.  Pharmacophore modeling and applications in drug discovery: challenges and recent advances. , 2010, Drug discovery today.

[55]  M. Brownstein,et al.  Aequorin-expressing mammalian cell lines used to report Ca2+ mobilization. , 1993, Cell calcium.

[56]  S. Nawoschik,et al.  Characterization of the 5-HT6 receptor coupled to Ca2+ signaling using an enabling chimeric G-protein. , 2003, European journal of pharmacology.

[57]  Jürgen Bajorath,et al.  Virtual screening methods that complement HTS. , 2004, Combinatorial chemistry & high throughput screening.